Navigation Links
Vioxx and Celebrex, now have alternatives

Kingston: Researchers at Queen's University and the University of Pennsylvania have been able to zero in on a possible reason for drugs like Celebrex and Vioxx, administered for treatment// of pain and swelling that carry a potential risk of triggering a heart problem

Co-author Colin Funk, a professor of Biochemistry and Physiology at Queen's, and Canada Research Chair in Molecular, Cellular and Physiological Medicine has expressed optimism of finding a new league of anti-inflammatory drugs that will help tide over this side-effects issue. The success rate of testing it on mice is a fore runner to it being tested on humans. The study is published in the on-line edition of the Journal of Clinical Investigation.

Selective inhibitors of COX-2 such as Vioxx, Bextra and Celebrex carry an increased risk of heart attack and stroke; there has been in-depth study on comprehending the reasons for this occurrence. Co-author with Dr. Funk on the study is Dr. Garret FitzGerald, director of Penn's Institute for Translational Medicine and Therapeutics. Funding comes from the U.S. National Institutes of Health and a grant from Merck.

"The trials showed that COX-2 inhibitors confer a small, but absolute cardiovascular risk using the same mechanism by which they relieve pain and inflammation," Dr. Funk reports.

"Selective inhibitors of mPGES-1 may retain much of the benefit of drugs like Vioxx and Celebrex, while diminishing the risk of heart attack and stroke by having precisely the opposite effect on prostacyclin [a protective fat that Vioxx and Celebrex depresses]," says Dr. FitzGerald.

Source :Eureka
'"/>




Page: 1

Related medicine news :

1. Increased Heart Attack Risk From Celebrex,Vioxx
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Could Long Tern Vioxx Users Suffer From Heart Attacks?
5. Doctor Grilled In Court For False Report About Vioxx Health Risk
6. Merck in the Dock Due To Vioxx
7. Vioxx Not Safe Even For Short Term Use
8. A Stroke of Bad Luck for Vioxx
9. Arcoxia Slammed –Nothing Better Than Vioxx Says FD
10. Increased Heart Attack Risk From Celebrex,Vioxx
11. Record growth of Soya-based dairy alternatives in Europe
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ORLEANS, La. (PRWEB) , ... July 21, 2017 ... ... to allow 4th-year medical students improve their chances of acceptance to a residency ... for those who have earned degrees outside the U.S. , According to data ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital ... adjustable beds used in such facilities are specially designed to accommodate patients with a ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, ...
(Date:7/20/2017)... MD (PRWEB) , ... July 20, 2017 , ... ... company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary ... million. , Proceeds will be used to complete regulatory submissions and fund final ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology: